ClinicalTrials.gg
CompletedNCT01519167Updated Mar 20, 2017Results posted

Open-Label, Safety Study Evaluating the Use of Dexmedetomidine in Pediatric Subjects Undergoing Procedure-Type Sedation

A Phase 4 interventional study of Dexmedetomidine and Midazolam in Ultrasound, CT Scans and MRIs, sponsored by Hospira, now a wholly owned subsidiary of Pfizer. Completed at 11 sites in 2 countries. Open to participants aged 28 Weeks to 16 Years. Per ClinicalTrials.gov, last updated 2017-03-20.

Sponsored by Hospira, now a wholly owned subsidiary of Pfizer (part of Pfizer) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
91
Allocation
Not applicable
Ages
28 Weeks to 16 Years
Sex
All
01

Study summary

The objective of this study is to evaluate the safety of dexmedetomidine in a pediatric population requiring non-intubated, spontaneous breathing, moderate to deep sedation (NI-MDS) for elective diagnostic or therapeutic procedures, expected to take more than 30 minutes.

Read the detailed description

This study was designed to evaluate the safety of a continuous infusion of dexmedetomidine (1 mcg/kg loading dose with 0.6 mcg/kg/hr initial maintenance dose and titrated between 0.2-1.0 mcg/kg/hr) administered to subjects requiring non-intubated, spontaneous breathing, moderate to deep sedation (NI-MDS) for elective diagnostic or therapeutic procedures that are expected to take more than 30 minutes.

02

Conditions studied

  • Ultrasound
  • CT Scans
  • MRIs
03

In context

Lead sponsor

Hospira, now a wholly owned subsidiary of Pfizer is the lead sponsor of 28 studies on the registry; none are open to participants now.

First submitted before Hospira became part of Pfizer.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
28 Weeks to 16 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subject is ≥28 weeks gestational age and \<17 years of age.

    • Preterm subjects ≥28 weeks through \<38 weeks, gestational age; (Note: Gestational age will be calculated as the time elapsed between the first day of the last menstrual period to the day of enrollment. If pregnancy was achieved using assisted reproductive technology, gestational age will be calculated by adding 2 weeks to the gestational age as calculated above.)
  2. Subject is (ASA) Physical Status I, II or III.
  3. Subject requires non-intubated, spontaneous breathing, moderate to deep sedation (NI-MDS) in an operating or procedure room with an an intensivist, anesthesiologist or dental anesthesiologist in attendance.
  4. Scheduled for an elective procedure that falls into one of the following three populations:

    • Non-invasive diagnostic/therapeutic procedures (NIDTP): including ultrasound (US), computed tomography (CT) scans, magnetic resonance imaging (MRI), cardiac catheterization, transthoracic echocardiogram (TTE);
    • Minimally invasive diagnostic/therapeutic procedures (MIDTP): including minimally invasive procedures performed under US or CT guidance (e.g. US or CT-guided solid organ ), and routine myocardial biopsies in cardiac transplant recipients;
    • Surgical procedures: including small surgical procedures (e.g. excisions, biopsies) and dental procedures (e.g. extractions, pulpectomy, pediatric rehabilitation dental procedures, filings and crowns).
  5. Duration of the procedure is expected to take at least 30 minutes to complete.
  6. If female, subject is non-lactating and is either:

    1. Not of , defined as pre-menarche, or surgically sterile due to bilateral tubal ligation, bilateral oophorectomy or hysterectomy.
    2. Of childbearing potential but is not pregnant at time of baseline and is practicing one of the following methods of : oral or parenteral contraceptives, double-barrier method, vasectomized partner, or abstinence from sexual intercourse.
  7. Subject's parent(s) or legally acceptable representative(s) has/have voluntarily signed and dated the document approved by the Institutional Review Board. Assent will be obtained where age-appropriate and according to state regulations.

Exclusion criteria

Exclusion Criteria:

  1. Subjects weight at the time of screening is less than 1000 g.
  2. Subject has received general anesthesia within 7 days prior to study drug administration.
  3. Subject has participated in an experimental/ drug study within 30 days prior to study drug administration.
  4. Subject has been exposed to dexmedetomidine within 48 hours prior to study drug administration.
  5. Subject that has been previously enrolled in this study (DEX-10-16).
  6. Subject requires endotracheal intubation or laryngeal mask airway (LMA).
  7. Subject is with neurological conditions that in the opinion of the Investigator will preclude reliable assessment of sedation scoring. Examples include, but are not limited to the following: cerebral palsy, autism, severe mental retardation, etc.
  8. Subject has central nervous system (CNS) disease with an anticipated potential for increased intracranial pressure, an uncontrolled seizure disorder and/or known psychiatric illness that could confound a normal response to sedative treatment.
  9. Subject requires epidural or spinal anesthesia.
  10. Subject has received treatment with an alpha-2 agonist or antagonist within 14 days prior to study drug administration.
  11. Subject has a known allergy to dexmedetomidine, midazolam or fentanyl.
  12. Subject is requiring cardiac catheterization for the purpose of conducting an electrophysiology (EP) evaluation or percutaneous intervention (i.e. angioplasty).
  13. Subject for whom opiates, benzodiazepines, dexmedetomidine or other alpha-2 agonists are .
  14. Subject has received an IV opioid within one hour, or oral/intramuscular (PO/IM) opioid within four hours, prior to the start of study drug administration.
  15. Subject has received any pre-induction medication (ie, ketamine, chloral hydrate, benzodiazepines) within 4 hours prior to the start of study drug administration.
  16. Subject has acute myocardial infarction recently diagnosed by confirmatory laboratory findings within 6 weeks of screening.
  17. Subject has moderate to severe sleep apnea syndrome.
  18. Subject has oxygen saturation (SpO2) ≤90% at screening or baseline, except for patients with known cyanotic heart disease undergoing cardiac catheterization.
  19. Subject has bradycardia immediately before dosing, according to respective age group.

    • ≥28 weeks to \<1 month: Heart Rate (HR) \<120 beats per minute (bpm)
    • 1 month to \<3 months: HR \<100 bpm
    • 3 months to \<6 months: HR \<90 bpm
    • 6 months to \<1 year: HR \<80 bpm
    • 1 year to \<2 years: HR \<70 bpm
    • 2 years to \<6 years: HR \<60 bpm
    • 6 years to \<12 years: HR \<55 bpm
    • 12 years to 17 years: HR \<50 bpm;

    Note: Subject can be reassessed after 5 minutes

  20. Subject has hypotension immediately before dosing, according to respective age group.

    • ≥28 weeks to \<1 month: \<60 mmHg (systolic blood pressure [SBP])
    • 1 month to \<12 months: \<70 mmHg (SBP)
    • 1 year to \<10 years: \<70 + (2 X age in years) mmHg (SBP)
    • 10 years to 17 years: \<90 mmHg (SBP);

    Note: Subject can be reassessed after 5 minutes

  21. Subject has a presence of second-degree or third-degree heart block at screening or baseline. The presence of a temporary or permanent pacemaker will waive this exclusion criterion.
  22. Subject has acute febrile illness, with a temperature (core or tympanic) ≥38.0°C.
  23. Subject has any other condition or factor which, in the Investigator's opinion, might increase the risk to the subject.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
91 participants (actual)

Study arms

  • Experimental
    Dexmedetomidine

    Drug: Dexmedetomidine · Drug: Midazolam · Drug: Fentanyl

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Subjects Who Had Success in Sedation

    Success in sedation was defined by a combined endpoint which was the combination of the following: 1. Subject had adequate level of sedation (University of Michigan Sedation Scale \[UMSS\] score between 1 to 3 \[minimally sedated to deeply sedated\] or Neonatal Pain, Agitation and Sedation Scale \[N-PASS\] score between -5 to -2 \[Light sedation\]) at least 80% of the time the subject was given the study drug. 2. Subject had successfully completed the procedure without a need for rescue sedation (Midazolam). 3. Subject had undergone the procedure without artificial ventilation or intervention to restore baseline or normal hemodynamic status

    Time frame: From baseline to end of post-treatment period (approximately 24 hours)

Secondary outcomes

  1. Number of Subjects Not Receiving Rescue Midazolam

    Number of subjects who did not receive any rescue midazolam for sedation during the study drug infusion.

    Time frame: During the treatment period, up to approximately 24 hours

  2. Number of Subjects Who Have Undergone Procedures Without Artificial Ventilation or Intervention

    Time frame: During the treatment period, up to approximately 24 hours

  3. Number of Subjects Who Were Adequately Sedated at Least 80% of Time

    Subjects who are adequately sedated (UMSS score of 1 to 3 or NPASS score of -5 to -2) at least 80% of the time sedated with the study drug

    Time frame: During the treatment period, up to approximately 24 hours

  4. Time to First Dose of Rescue Midazolam From Start of Dexmedetomidine Infusion

    Kaplan-Meier estimates of time in minutes to first dose of rescue midazolam from onset of study drug infusion

    Time frame: During the treatment period, up to approximately 24 hours

  5. Frequency of Midazolam Required for Sedation

    Frequency of rescue sedation (midazolam) required to maintain a subject within the target sedation range (UMSS score greater than 1 or N-PASS score less than -2).

    Time frame: During the treatment period, up to approximately 24 hours

  6. Frequency of Fentanyl Use for Analgesia

    Frequency of rescue analgesia (fentanyl) required from the start of IV sedation to completion of the procedure.

    Time frame: During the treatment period, up to approximately 24 hours

  7. Total Amount of Rescue Sedation (Midazolam)

    Total amount of rescue sedation (midazolam) required from the start of IV sedation to completion of the procedure

    Time frame: During the treatment period, up to approximately 24 hours

  8. Total Amount of Rescue Analgesia (Fentanyl)

    Total amount of rescue analgesia (fentanyl) required from the start of IV sedation to completion of the procedure

    Time frame: During the treatment period, up to approximately 24 hours

  9. Number of Subjects Converted to Alternative Sedation or Anesthetic Therapy Due to Failure of Treatment of Study Drug and Rescue Medication

    Time frame: During the treatment period, up to approximately 24 hours

07

Results

Posted Aug 14, 2015

Participant flow

Participant flow — Overall Study
MilestoneDose Level 1Dose Level 2
Started189
Completed181
Not completed08
Withdrew: Diagnostic/therapeuticprocedurecompleted03
Withdrew: Adverse event01
Withdrew: Lack of efficacy01
Withdrew: Medical condition changes&deep sedation02
Withdrew: Physician decision01

Outcome measures

PrimaryNumber of Subjects Who Had Success in Sedation

Success in sedation was defined by a combined endpoint which was the combination of the following: 1. Subject had adequate level of sedation (University of Michigan Sedation Scale \[UMSS\] score between 1 to 3 \[minimally sedated to deeply sedated\] or Neonatal Pain, Agitation and Sedation Scale \[N-PASS\] score between -5 to -2 \[Light sedation\]) at least 80% of the time the subject was given the study drug. 2. Subject had successfully completed the procedure without a need for rescue sedation (Midazolam). 3. Subject had undergone the procedure without artificial ventilation or intervention to restore baseline or normal hemodynamic status

Time frame:
From baseline to end of post-treatment period (approximately 24 hours)
Reported as:
Number · participants
Number of Subjects Who Had Success in Sedation
participantsDose Level 1Dose Level 2
NIDTP (n=1, 40)02
MIDTP (n=0, 25)00
Surgical procedures (n=0, 12)00
SecondaryNumber of Subjects Not Receiving Rescue Midazolam

Number of subjects who did not receive any rescue midazolam for sedation during the study drug infusion.

Time frame:
During the treatment period, up to approximately 24 hours
Reported as:
Number · participants
Number of Subjects Not Receiving Rescue Midazolam
participantsDose Level 1Dose Level 2
NIDTP (n=1, 40)112
MIDTP (n=0, 25)05
Surgical procedures (n=0, 12)01
SecondaryNumber of Subjects Who Have Undergone Procedures Without Artificial Ventilation or Intervention
Time frame:
During the treatment period, up to approximately 24 hours
Reported as:
Number · participants
Number of Subjects Who Have Undergone Procedures Without Artificial Ventilation or Intervention
participantsDose Level 1Dose Level 2
NIDTP (n=1, 40)137
MIDTP (n=0, 25)019
Surgical procedures (n=0, 12)012
SecondaryNumber of Subjects Who Were Adequately Sedated at Least 80% of Time

Subjects who are adequately sedated (UMSS score of 1 to 3 or NPASS score of -5 to -2) at least 80% of the time sedated with the study drug

Time frame:
During the treatment period, up to approximately 24 hours
Reported as:
Number · participants
Number of Subjects Who Were Adequately Sedated at Least 80% of Time
participantsDose Level 1Dose Level 2
NIDTP (n=1, 40)021
MIDTP (n=0, 25)07
Surgical procedures (n=0, 12)02
SecondaryTime to First Dose of Rescue Midazolam From Start of Dexmedetomidine Infusion

Kaplan-Meier estimates of time in minutes to first dose of rescue midazolam from onset of study drug infusion

Time frame:
During the treatment period, up to approximately 24 hours
Reported as:
Median · Hours
Time to First Dose of Rescue Midazolam From Start of Dexmedetomidine Infusion
HoursDose Level 1Dose Level 2
NIDTP (n=1, 40)NA23.5 (16.00 to 28.00)
MIDTP (n=0, 25)NA20.00 (17.00 to 34.00)
Surgical procedures (n=0, 12)NA20.00 (15.00 to 25.00)
SecondaryFrequency of Midazolam Required for Sedation

Frequency of rescue sedation (midazolam) required to maintain a subject within the target sedation range (UMSS score greater than 1 or N-PASS score less than -2).

Time frame:
During the treatment period, up to approximately 24 hours
Reported as:
Median · Occurrence
Frequency of Midazolam Required for Sedation
OccurrenceDose Level 1Dose Level 2
NIDTP (n=0, 28)—2 (1 to 4)
MIDTP (n=0, 20)—1 (1 to 2)
Surgical procedures (n=0, 11)—1 (1 to 2)
SecondaryFrequency of Fentanyl Use for Analgesia

Frequency of rescue analgesia (fentanyl) required from the start of IV sedation to completion of the procedure.

Time frame:
During the treatment period, up to approximately 24 hours
Reported as:
Median · Occurrence
Frequency of Fentanyl Use for Analgesia
OccurrenceDose Level 1Dose Level 2
NIDTP (n=0, 6)—1 (1 to 3)
MIDTP (n=0, 22)—1 (1 to 5)
Surgical procedures (n=0, 12)—2.50 (1 to 5)
SecondaryTotal Amount of Rescue Sedation (Midazolam)

Total amount of rescue sedation (midazolam) required from the start of IV sedation to completion of the procedure

Time frame:
During the treatment period, up to approximately 24 hours
Reported as:
Mean · milligram
Total Amount of Rescue Sedation (Midazolam)
milligramDose Level 1Dose Level 2
NIDTP (n=0, 28)—2.62 ± 1.611
MIDTP (n=0, 20)—1.70 ± 0.767
Surgical procedures (n=0, 11)—2.45 ± 0.907
SecondaryTotal Amount of Rescue Analgesia (Fentanyl)

Total amount of rescue analgesia (fentanyl) required from the start of IV sedation to completion of the procedure

Time frame:
During the treatment period, up to approximately 24 hours
Reported as:
Mean · microgram
Total Amount of Rescue Analgesia (Fentanyl)
microgramDose Level 1Dose Level 2
NIDTP (n=0, 6)—10.83 ± 8.010
MIDTP (n=0, 22)—61.86 ± 65.740
Surgical procedures (n=0, 12)—104.83 ± 72.007
SecondaryNumber of Subjects Converted to Alternative Sedation or Anesthetic Therapy Due to Failure of Treatment of Study Drug and Rescue Medication
Time frame:
During the treatment period, up to approximately 24 hours
Reported as:
Number · Participants
Number of Subjects Converted to Alternative Sedation or Anesthetic Therapy Due to Failure of Treatment of Study Drug and Rescue Medication
ParticipantsDose Level 1Dose Level 2
NIDTP (n=1, 40)00
MIDTP (n=0, 25)00
Surgical procedures (n=0, 12)02

Adverse events

Collected over Non-serious adverse events from start of study drug administration until 24(±12) hours following study drug discontinuation. Reported serious adverse events from the time the subject signed informed consent until 30 days after study drug discontinuation.. Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Dose Level 1—0/1 (0%)1/1 (100%)
Dose Level 2—1/89 (1.1%)66/89 (74.2%)
Most frequent serious events
Most frequent serious events
EventDose Level 1Dose Level 2
SyncopeNervous system disorders0/11/89
Most frequent other events
Showing 10 of 17
Most frequent other events
EventDose Level 1Dose Level 2
Respiratory depressionRespiratory, thoracic and mediastinal disorders1/153/89
HypotensionVascular disorders0/137/89
BradycardiaCardiac disorders0/14/89
Blood pressure systolic decreasedInvestigations0/13/89
HeadacheNervous system disorders0/13/89
NauseaGastrointestinal disorders0/12/89
VomitingGastrointestinal disorders0/12/89
Blood pressure diastolic decreasedInvestigations0/12/89
HypoxiaRespiratory, thoracic and mediastinal disorders0/12/89
HypertensionVascular disorders0/12/89

Baseline characteristics

Safety Evaluable Population: All subjects who receive any amount of study drug. All safety analyses will be performed on this population.

Age, Continuous
Age, Continuous(years)Dose Level 1Dose Level 2Total
Mean0.1 (0.1 to 0.1)7.97 (0.3 to 17.3)7.89 (0.1 to 17.3)
Sex: Female, Male
Sex: Female, Male(Participants)Dose Level 1Dose Level 2Total
Female04141
Male14849
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Dose Level 1Dose Level 2Total
Hispanic or Latino02323
Not Hispanic or Latino16667
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Dose Level 1Dose Level 2Total
American Indian or Alaska Native000
Asian011
Native Hawaiian or Other Pacific Islander000
Black or African American12223
White06060
More than one race000
Unknown or Not Reported066
08

Study locations

11 sites
  • Little Rock, Arkansas 72202, United States
  • Anaheim, California 92801, United States
  • Stanford, California 94305, United States
  • Miami, Florida 33136, United States
  • Durham, North Carolina 27710, United States
  • Pittsburgh, Pennsylvania 15224, United States
  • Nashville, Tennessee 37232-9070, United States
  • Dallas, Texas 75235, United States
  • Sandy, Utah 84096, United States
  • San Juan, 00936-5067, Puerto Rico
  • San Juan, 00936, Puerto Rico
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2012, a primary completion of Jan 2014 and a completion of Jan 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2015, 1 year 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 24, 2012
First posted
Jan 26, 2012
Start
Oct 2012
Primary completionActual
Jan 2014
CompletionActual
Jan 2014
Results first posted
Aug 14, 2015
Last update
Mar 20, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 20, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01519167
Responsible party
Sponsor
First posted
Jan 26, 2012
Start date
Oct 2012
Primary completion
Jan 2014
Completion
Jan 2014
Results posted
Aug 14, 2015
Last update
Mar 20, 2017

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dexmedetomidine

Start the discussion